CardioGenics Holdings Debt 2024

CardioGenics Holdings Aktienanalyse

What does CardioGenics Holdings do?

The company CardioGenics Holdings Inc. is headquartered in Mississauga, Canada, and is a leading company in the field of cardiovascular disease diagnostics. The company was founded in 1997 by Walter Witoshkin, who continues to serve as CEO today. CardioGenics' business model is based on the development and marketing of solutions for fast, reliable, and cost-effective diagnosis of cardiovascular diseases. The focus is especially on the diagnosis of heart attacks and heart failure. To achieve these goals, CardioGenics has developed various divisions. The most important division is the production of in-vitro diagnostics (IVD). These are tests that are performed based on blood samples, enabling doctors to make a quick and easy diagnosis. Another important area of CardioGenics is the development of diagnostics based on immunassays. Antibodies are used to identify specific proteins in the blood that indicate a certain disease. This allows early predictions about the risk of cardiovascular diseases. In addition to the development of diagnostics, CardioGenics is also active in the field of research and development. The company works closely with academic institutions and research partners to develop and market innovative solutions in the field of diagnostics. CardioGenics' products include various IVD tests specifically developed for the diagnosis of cardiovascular diseases. One of the most important products is the QL Care Analyzer, a fully automated system for the rapid determination of Troponin I, a protein released in the blood during heart attacks. Another important product of CardioGenics is the Myo9 test. This test is an immunassay that allows doctors to determine the risk of cardiovascular diseases in certain patient groups. The test is mainly used for patients with diabetes, as they have an increased risk of cardiovascular diseases. Furthermore, CardioGenics also offers various services such as training and user support for its products. The company works closely with customers to provide them with the best possible support in the application of IVD tests and other diagnostic products. In recent years, CardioGenics has expanded its business internationally and launched its products in various countries. The company also has a strong presence at leading scientific conferences and trade fairs to showcase its products and services and share its expertise in the field of cardiovascular diagnostics. In summary, CardioGenics is an established company in the field of cardiovascular disease diagnostics. With a wide range of diagnostic products and a strong focus on research and development, the company is well positioned to continue growing and strengthen its presence in the international market. CardioGenics Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding CardioGenics Holdings's Debt Structure

CardioGenics Holdings's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing CardioGenics Holdings's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to CardioGenics Holdings’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in CardioGenics Holdings’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about CardioGenics Holdings Stock

What is the debt of CardioGenics Holdings this year?

CardioGenics Holdings has a debt level of 0 USD this year.

What was the debt of CardioGenics Holdings compared to the previous year?

The debt of CardioGenics Holdings has increased by 0% compared to the previous year dropped.

What are the consequences of high debt for investors in CardioGenics Holdings?

High debt can pose a risk for investors of CardioGenics Holdings, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of CardioGenics Holdings?

Low debt means that CardioGenics Holdings has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from CardioGenics Holdings affect the company?

An increase in debt of CardioGenics Holdings can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of CardioGenics Holdings affect the company?

A reduction in debt of CardioGenics Holdings can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of CardioGenics Holdings?

Some factors that can influence the debt of CardioGenics Holdings include investments, acquisitions, operating costs, and revenue development.

Why are the debts of CardioGenics Holdings so important for investors?

The debts of CardioGenics Holdings are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can CardioGenics Holdings take to change the debt?

To change the debt, CardioGenics Holdings can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does CardioGenics Holdings pay?

Over the past 12 months, CardioGenics Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CardioGenics Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of CardioGenics Holdings?

The current dividend yield of CardioGenics Holdings is .

When does CardioGenics Holdings pay dividends?

CardioGenics Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CardioGenics Holdings?

CardioGenics Holdings paid dividends every year for the past 0 years.

What is the dividend of CardioGenics Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CardioGenics Holdings located?

CardioGenics Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von CardioGenics Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CardioGenics Holdings from 6/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/12/2024.

When did CardioGenics Holdings pay the last dividend?

The last dividend was paid out on 6/12/2024.

What was the dividend of CardioGenics Holdings in the year 2023?

In the year 2023, CardioGenics Holdings distributed 0 USD as dividends.

In which currency does CardioGenics Holdings pay out the dividend?

The dividends of CardioGenics Holdings are distributed in USD.